高截留量对比高通量血液透析治疗硼替佐米化疗的多发性骨髓瘤管型肾病(EuLITE):2期随机对照试验
EuLITE是一项开放标签、2期、多中心随机对照试验,纳入90例新诊断多发性骨髓瘤、活检证实管型肾病且需透析的急性肾损伤患者,随机接受高截留量血液透析(HCO-HD)或标准高通量血液透析(HF-HD),均接受硼替佐米为主的化疗。主要终点为随机分组后90天脱离透析,HCO-HD组24例(56%)vs HF-HD组24例(51%)(相对风险1.09,95%CI 0.74-1.61;p=0.81),未达统计学显著。作者结论认为HCO-HD未改善临床结局,结果不支持推进3期研究。
要点
- 90天脱离透析率HCO-HD组56% vs HF-HD组51%,相对风险1.09(95%CI 0.74-1.61;p=0.81),无显著差异。
- 2年随访期间HCO-HD组报告98例严重不良事件,HF-HD组报告82例。
- 前90天HCO-HD组报告26例感染(含14例肺部感染),HF-HD组报告13例感染(含3例肺部感染)。
核心结论
- 在这项2期研究中,对于新诊断多发性骨髓瘤、因急性肾损伤需透析且接受硼替佐米为主化疗的管型肾病患者,HCO-HD相对于HF-HD未改善临床结局。
- 这些结果不支持在这些患者中推进HCO-HD的3期研究。
研究设计与样本
- 开放标签、2期、多中心、随机对照试验(EuLITE),在英国和德国的16家医院肾脏科招募患者。
- 纳入新诊断多发性骨髓瘤、活检证实管型肾病、需透析的急性肾损伤患者,按1:1随机分为HCO-HD组(每次6-8小时)或标准HF-HD组,按年龄和中心分层。
- 患者接受硼替佐米、多柔比星和地塞米松化疗,随访2年;主要终点为随机分组后90天脱离透析,在意向性治疗人群中评估。
- 2008年6月7日至2013年9月18日共招募90例患者,HCO-HD组43例(48%),HF-HD组47例(52%);全部90例纳入主要终点分析。
主要发现
- 90天后HCO-HD组24例(56%)vs HF-HD组24例(51%)脱离透析(相对风险1.09,95%CI 0.74-1.61;p=0.81)。
- HF-HD组1例(2%)患者在治疗前撤回知情同意;治疗期间HCO-HD组9例(21%)vs HF-HD组2例(4%)停止试验治疗。
- 2年随访期间HCO-HD组报告98例严重不良事件,HF-HD组报告82例;最常见为感染及心血管、血栓和肌肉骨骼系统相关不良事件。
- 前90天HCO-HD组报告26例感染(含14例肺部感染),HF-HD组报告13例感染(含3例肺部感染)。
临床怎么用
- 原文结论认为HCO-HD相对于HF-HD未改善临床结局,结果不支持在这些患者中推进HCO-HD的3期研究。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In multiple myeloma, severe acute kidney injury due to myeloma cast nephropathy is caused by pathogenic free light chain immunoglobulin in serum. High cutoff haemodialysis (HCO-HD) can remove large quantities of free light chain immunoglobulin from serum, but its effect on clinical outcomes is uncertain. We therefore aimed to assess whether HCO-HD could increase the frequency of renal recovery in patients with de novo multiple myeloma, severe acute kidney injury, and myeloma cast nephropathy relative to treatment with standard high-flux haemodialysis (HF-HD). METHODS: In this open-label, phase 2, multicentre, randomised controlled trial (EuLITE), we recruited patients with newly diagnosed multiple myeloma, biopsy-confirmed cast nephropathy, and acute kidney injury that required dialysis from renal services in 16 hospitals in the UK and Germany. Patients were randomly assigned (1:1) by random number generation to receive intensive HCO-HD (in sessions lasting 6-8 h) or standard HF-HD and they were stratified by age and centre. Patients and the medical staff treating them were not masked to treatment allocation. Patients received bortezomib, doxorubicin, and dexamethasone chemotherapy, and were then followed up for 2 years. The primary outcome was independence from dialysis at 90 days after random allocation to groups, which was assessed in an intention-to-treat population. The trial has completed follow-up, and is registered at the ISRCTN registry, number ISRCTN45967602. FINDINGS: Between June 7, 2008, and Sept 18, 2013, we recruited 90 patients, of whom 43 (48%) were randomly assigned to receive HCO-HD and 47 (52%) were randomly assigned to receive HF-HD. All 90 patients were included in the analysis of the primary outcome. One (2%) patient from the HF-HD group withdrew consent before receiving treatment. During treatment, nine (21%) patients from the HCO-HD group and two (4%) patients in the HF-HD group discontinued trial treatment. After 90 days, 24 (56%) patients in the HCO-HD group and 24 (51%) patients in the HF-HD group were independent from dialysis (relative risk 1·09, 95% CI 0·74-1·61; p=0·81). During the 2-year follow-up, 98 serious adverse events were reported in the HCO-HD group and 82 serious adverse events were reported in the HF-HD group. The most common serious adverse events were infections and adverse events related to the cardiovascular and thrombotic and musculoskeletal systems. During the first 90 days, 26 infections were reported in the HCO-HD group and 13 infections were reported in the HF-HD group, including 14 lung infections in the HCO-HD group and three lung infections in the HF-HD group. INTERPRETATION: In this phase 2 study, HCO-HD did not improve clinical outcomes for patients with de novo multiple myeloma and myeloma cast nephropathy who required haemodialysis for acute kidney injury and who received a bortezomib-based chemotherapy regimen relative to those receiving HF-HD. These results do not support proceeding to a phase 3 study for HCO-HD in these patients. FUNDING: Gambro, Janssen, and Binding Site.
引用
- Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019. PMID: 30872075. doi:10.1016/S2352-3026(19)30014-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。